ASX Share rice
Thu 13 May 2021 - 12:09:pm (Sydney)

BOT Share Price

BOTANIX PHARMACEUTICALS LTDBOTPharmaceuticals, Biotechnology & Life Sciences

BOT Company Information

Name:

Botanix Pharmaceuticals Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

50 Angove Street North Perth WA Australia 6006

Phone:

61 8 6555 2945

Full Time Employees:

1

MD, Pres & Exec. Chairman:

Mr. Vincent P. Ippolito

Chief Scientific Officer & Exec. Director:

Dr. Henry William Bosch

Exec. Director:

Mr. Matthew Callahan L.L.B., M.B.A., MBA LLB

Chief Medical Officer:

Dr. Clarence L. Young

Head of Commercial:

Ms. Lynda Berne

Company Sec.:

Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA

Company Overview:

Botanix Pharmaceuticals Limited, a clinical stage synthetic cannabinoid pharmaceutical company, engages in the research and development of dermatology and antimicrobial products in Australia. It offers BTX 1503, a transdermal gel formulation for the treatment of serious acne in adults and teenagers that has completed Phase II clinical trials; BTX 1801, which is in Phase IIa clinical trials for the treatment of staphylococcus aureus and methicillin resistant staphylococcus aureus; and BTX 1702 that is in Phase II clinical trials for the treatment of papulopustular rosacea. The company was incorporated in 1984 and is based in North Perth, Australia.

BOT Share Price Information

Shares Issued:

0.97B

Market Capitalisation:

$75.91M

Revenue (TTM):

$6.89M

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.022

Profit Margin:

-1.3165

Operating Margin (TTM):

$-1.32

Return On Assets (TTM):

$-0.18

Return On Equity (TTM):

$-0.31

Quarterly Revenue Growth (YOY):

-0.089

Gross Profit(TTM):

$-6,135,137

Diluted Earnings Per Share (TTM):

$-0.01

BOT CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-151,191

Change To Liabilities:

$-3,409,545

Total Cashflow From Investing Activities:

$-151,191

Net Borrowings:

$-23,079

Net Income:

$-16,730,708

Total Cash From Operating Activities:

$-17,358,586

Depreciation:

$102.28K

Other Cashflow From Investing Activities:

$-61,140

Change To Account Receivables:

$351.16K

Sale Purchase Of Stock:

$40.49M

Capital Expenditures:

$90.05K

BOT Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-16,730,710

Net Income:

$-16,730,710

Operating Income:

$-24,078,480

Other Operating Expenses:

$780.82K

Interest Expense:

$50.98K

Total Revenue:

$180.58K

BOT Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$1.67M

Total Stockholder Equity:

$23.64M

Total Assets:

$25.31M

Common Stock:

$71.41M

Retained Earnings:

$-51,263,208

Cash:

$24.65M

Total Current Liabilities:

$1.38M

Property - Plant & Equipment:

$445.04K

Net Tangible Assets:

$23.64M

Long-Term Investments:

$88.73K

Total Current Assets:

$24.78M

Net Receivables:

$130.64K

Short-Term Investments:

$533.77K

Accounts Payable:

$1.18M

Short-Term Investments:

$533.77

Non Current Liabilities Total:

$296.30K

BOT Share Price History

BOT News

08 Mar, 2021
We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...
02 Feb, 2021
Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product for the eradication of Staphylococcus Aureus (Staph).
08 Dec, 2020
It might seem bad, but the worst that can happen when you buy a stock (without leverage) is that its share price goes...
09 Oct, 2020
We feel now is a pretty good time to analyse Botanix Pharmaceuticals Limited's (ASX:BOT) business as it appears the...
10 Aug, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
We can readily understand why investors are attracted to unprofitable companies. For example, although...